For the Inventor, By the Inventor

Enter assignee name

Ann Arbor, MI, United States of America

Lycera Corporation

USPTO Granted Patents = 36

% Expired Patents = 72.2

CIPO Patents = 3

EPO Patents = 9

Forward Citations = 222

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Thomas Daniel Aicher (23 out of 53 patents)

Clarke Bentley Taylor (21 out of 30 patents)

Chad A VanHuis (14 out of 15 patents)

4. Peter Laurence Toogood (14 out of 32 patents)

5. Chad A Van Huis (12 out of 12 patents)

6. Alexander Ross Hurd (12 out of 16 patents)

7. Vladimir Simov (8 out of 13 patents)

8. Kenneth Jay Barr (8 out of 44 patents)

9. William L Thomas (7 out of 265 patents)

10. Catherine M White (7 out of 19 patents)

11. Gary D Glick (7 out of 66 patents)

12. Blair T Lapointe (6 out of 18 patents)

13. Donald James Skalitzky (6 out of 8 patents)

14. Nunzio Sciammetta (5 out of 24 patents)

15. Matthew H Daniels (5 out of 19 patents)

36 patents: Sort by Forward Citations

1. 10745364 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2020-08-18),

2. 10611740 - Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2020-04-07),

3. 10556898 - Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease (2020-02-11),

4. 10532088 - Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods (2020-01-14),

5. 10442798 - Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-10-15),

6. 10421751 - Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-09-24),

7. 10392350 - N-substituted pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof (2019-08-27),

8. 10377768 - Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-08-13),

9. 10364237 - Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-07-30),

10. 10221146 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-03-05),

11. 10208061 - Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-02-19),

12. 10189777 - Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease (2019-01-29),

13. 10112935 - Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease (2018-10-30),

14. 10085972 - [object Object] (2018-10-02),

15. 9932313 - [object Object] (2018-04-03),

Lycera Corporation is a biopharmaceutical company focused on developing innovative oral immune modulators for the treatment of autoimmune diseases and cancer. The company's proprietary platform enables the discovery of small molecules that target immune cells to restore and maintain normal immune function. Lycera's goal is to create safe and effective therapies that provide substantial benefits to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Lycera Corporation

36 Patents

#24 in Ann Arbor, MI

#361 in Michigan

#9,486 in US

#18,677 in the World

Ann Arbor, MI, United States of America

Lycera Corporation

Forward Citations = 222

35 inventors:

Thomas Daniel Aicher (23 out of 53 patents)

Clarke Bentley Taylor (21 out of 30 patents)

Chad A VanHuis (14 out of 15 patents)

4. Peter Laurence Toogood (14 out of 32 patents)

5. Chad A Van Huis (12 out of 12 patents)

Please report any incorrect information to [email protected]

Loading…